Home Blog of Signal Transduction Stem Cells & Wnt Hedgehog The hedgehog signaling pathway, as the target in cancer treatment

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

The hedgehog signaling pathway, as the target in cancer treatment

     The hedgehog(Hh) signaling pathway is one of the key regulators of animal development and is present in all bilaterians. The Hh family of proteins have since been recognized to involve in many fundamental processes in vertebrate embryonic development and play an important role in regulating cell fate, patterning, proliferation, survival and differentiation of many different regions. In the embryonic period, dysfunction in the Hh signaling pathway will lead to brain, facial and other midline defects such as holoprosencephaly, cyclopia, absent nose or cleft palate.

     In adults, the Hh signaling pathway is still active and contributes to regulation of tissue repair and renewal. However, disorder of this pathway will cause abnormal cell proliferation and differentiation and thus result in tumorigenesis or tumor develooment in a variety of tissues.

     Accordingly, the Hh signaling pathway has also recently been considered as a therapeutic target in cancers. Cyclopamine is the first found Hh pathway inhibitor to induce cyclopia and holoprosencephaly in lambs[1]. Subsequently, many novel and more potent derivatives have been synthesized with greater oral bioavailability, including SANT1-SANT4, CUR-61414, HhAntag-691 and GDC-0449. And the inhibitors are demonstrated to produce the inhibitory effects by suppressing the transmembrane receptor protein Smoothened (SMO).

      There are three basic models which is observed for Hh pathway activity in cancers: ligand independent, mutation driven; autocrine, ligand dependent; paracrine, ligand dependent[2]. According to the differences of causes, different target inhibitors are needed for treatment.

      At present, the advances of Hh pathway inhibitors have been constantly reported in the ongoing preclinical and clinical trials, thus Hh pathway inhibitors represent an important new class of therapeutic agents in the treatment of cancers.
 

References

[1]. J Anat 1971; 110: 507.

[2]. Trends Pharmacol Sci 2009; 30: 303-312.

Related Products

Cat.No. Product Name Information
S1146 Cyclopamine Cyclopamine (11-deoxojervine) is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.
S1082 Vismodegib (GDC-0449) Vismodegib (GDC-0449) is a potent, novel and specific hedgehog inhibitor with IC50 of 3 nM and also inhibits P-gp with IC50 of 3.0 μM in a cell-free assay.

Related Targets

Hedgehog